Ocugen outlicenses gene therapy to Celairis (OCGN:NASDAQ)

Ocugen outlicenses gene therapy to Celairis (OCGN:NASDAQ)

Ocugen (OCGN) grants Celairis exclusive rights to gene therapy, OCU400, in Australia, New Zealand, and ASEAN for up to $7.1M. Read more here.

Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in ...

Celairis receives exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa (RP), in Australia, New Zealand, and member states of the Association of Southeast Asian Nations (ASEAN) markets

Ocugen Secures Gene Therapy Licenses Ahead of Phase 3 Results

MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has secured a Middle East and North Africa licensing agreement worth up to $259 million in potential payments and received provisional regulatory approval …

Release - Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN - Channelchek

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, and Celairis Therapeutics Holdings Pty Ltd. (“Celairis”), a Sydney-based in-licensing, development, and commercialization biopharmaceutical company focused on Australia, New Zealand, Taiwan, and ASEAN, today announced the execution of an exclusive license agreement (the “License Agreement”) granting Celairis an exc…